Home Featured Page 20

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists...

Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences...

From Individualism to Connection: How Psychedelics and Group Therapy Can Heal...

Tripping Over Trump: Will the New Administration Embrace Psychedelic Exceptionalism or...

NEW REPORT: Psychedelics at Work – Mapping the Path of the...

How Safe is Ibogaine Therapy? The Delicate Balance of Risk and...

Psychedelic Literacy for Veterans: Bridging the Knowledge Gap in PTSD Recovery

Why Psychedelic Research is Booming: Current Trends and Hurdles

Question 4 Fails: Massachusetts Says No to State-Regulated Psychedelics Access and...

1...192021...295 Page 20 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Psychedelic Investor Survey Q3 2024

Dispatch From the DEA: DOI and DOC on Trial As Scientists...

Pα+ Psychedelic Bulletin #180: Mass. Psychedelics Ballot Post-Mortem Begins; Cybin Commences...

From Individualism to Connection: How Psychedelics and Group Therapy Can Heal...

Tripping Over Trump: Will the New Administration Embrace Psychedelic Exceptionalism or...

NEW REPORT: Psychedelics at Work – Mapping the Path of the...

How Safe is Ibogaine Therapy? The Delicate Balance of Risk and...

Psychedelic Literacy for Veterans: Bridging the Knowledge Gap in PTSD Recovery

Why Psychedelic Research is Booming: Current Trends and Hurdles

Question 4 Fails: Massachusetts Says No to State-Regulated Psychedelics Access and...

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY